Valproic Acid May Exerts Its Cytotoxic Effect Through Rassf1a Expression Induction in Acute Myeloid Leukemia Publisher Pubmed



Davood ZA¹ ; Shamsi S¹ ; Ghaedi H¹ ; Sahand RI² ; Mojtaba G¹ ; Mahdi T¹ ; Reza M¹ ; Ebrahimi MJ¹ ; Mirimoosavi RS³ ; Boosaliki S¹ ; Davood OM¹ Show Affiliations
Source: Tumor Biology Published:2016

Abstract

In acute myeloid leukemia (AML), despite the acceptance of standard intensive chemotherapy as an optimal induction regimen for all age groups, in the elderly patients, the best treatment should meet the challenge of multiple factors like age, comorbidities, and cytogenetics, making them ineligible for standard induction chemotherapy. Using the current low-intensity therapies like decitabine, azacitidine, and low-dose cytarabine as a single arm, outcomes for these patients remain poor. As a histone deacetylase inhibitor valproic acid (VPA) exhibit anticancer activity by triggering apoptosis, the mechanism of which is not yet completely clarified. To explore the possible connection between VPA treatment and the Hippo pathway as an apoptosis stimulating route, we also explore the expression of major components of this pathway and for the first time we postulate a relationship between VPA treatment and cell death induction through RASSF1A expression induction. Furthermore, we demonstrate that autophagy inhibition by chloroquine (CQ) significantly augmented the cytotoxic effect of VPA on AML cells, especially in those with unfavorable and normal karyotype. Regarding that VPA and CQ are well-tolerated drugs and our presumptive results of usefulness of VPA + CQ in three cytogenetic risk groups of AML, this combinatorial therapy could represent an attractive treatment option for older AML patients unfit for intensive therapy. © 2016, International Society of Oncology and BioMarkers (ISOBM).